An open-label, phase I/II trial to determine the maximum tolerated dose and investigate safety, pharmacokinetics and efficacy of BI 836858, an unconjugated anti-CD33 monoclonal antibody, in combination with decitabine in patients with acute myeloid leukemia.
作者信息
Fiedler Walter, Montesinos Pau, Schliemann Christoph, Middeke Jan, Vasu Sumithira, Scholz Christian W, Esteve Jordi, Mondal Shoubhik, Rüter Björn, Burkard Ute, Osswald Annika, Blum William
机构信息
Department of Oncology, Hematology and Bone Marrow Transplantation with Section Pneumology, University Medical Center Hamburg-Eppendorf, Hamburg.
Hospital Universitari i Politecnic La Fe, Valencia, Spain; CIBERONC, Instituto Carlos III, Madrid.
出版信息
Haematologica. 2022 Dec 1;107(12):2977-2982. doi: 10.3324/haematol.2022.281128.
Abstract
摘要
Zotero 插件